跳至主要内容
临床试验/NL-OMON49487
NL-OMON49487尚未招募不适用

Metacognitive therapy for Generalized Anxiety Disorder in patients with a schizophrenia-spectrum disorder - MCT for GAD with schizophrenia-spectrum disorder

Parnassia Bavo Groep (Den Haag)0 个研究点目标入组 9 人开始时间: 待定最近更新:

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
9

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • 1. Age between 18-65;
  • 2. primary diagnosis of schizophrenia-spectrum disorder according to DSM-5
  • 3. A score of 10 or higher on the GAD-7, a diagnostic screening list for GAD
  • 4. A clinically significant degree of worrying, shown by a high score (* 49) on
  • the Penn State Worry Questionnaire
  • 5. In case of intended radical changes in the field of pharmacotherapy,
  • patients can only enter the study if the dose is stable for at least one month.

排除标准

  • Patients are excluded when:
  • 1. they are unable or seem unable to give informed consent;
  • 2. they don't sufficiently master the dutch language to undergo treatment
  • without an interpreter
  • 3. there is alcohol or drug abuse that interferes with treatment
  • 4. they have an IQ of 70 or below
  • 5. they have an organic disorder

研究者

发起方
Parnassia Bavo Groep (Den Haag)

相似试验